Pirenzepine and carbenozolone in gastric ulcer. Preliminary results of a multicentre double-blind controlled clinical trial.
Pirenzepine (PRZ) 75 mg/day for 1 week followed by 50 mg/day for 3 weeks did not show a good activity in gastric ulcer healing in comparison to carbenoxolone (CB) (300 mg/day for 1 week followed by 200 mg/day for 3 weeks). The tolerability of PRZ seemed to be better than that of CB. The increase in the daily dose of PRZ to 100 mg/day for 4 weeks led to better results in the patients who have completed satisfactorily the treatment up to now. PRZ's tolerability was greater than CB's. The results of this study are preliminary to further trial.
D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000627:therapeutic use*; D002229:Carbenoxolone / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010890:Pirenzepine; D013276:Stomach Ulcer / Q000188:drug therapy*
D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D010879:Piperazines; D010890:Pirenzepine; D002229:Carbenoxolone; D006034:Glycyrrhetinic Acid